Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
This biotech growth stock is climbing its way up a base on its way to a buy point. The company's sales are expected to continue to soar.
Procept BioRobotics and Ascendis Pharma may not show profits but the stocks have outperformed the S&P 500 in 2024. Shares are near buy points.